Viking Therapeutics, Inc.
VKTX
Rangering i aksjer
#4566
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Aksjekurs
$26.38
Markedsverdi
$3.35B
Endring (1 dag)
-1.23%
Endring (1 år)
-20.01%
Land
US
Handel Viking Therapeutics, Inc. (VKTX)
Kategori
Healthcare
Historikk for aksjesplitt for Viking Therapeutics, Inc. (VKTX)
Aksjen Viking Therapeutics, Inc. (symbol: VKTX) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én VKTX-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 VKTX-aksjer.
Den nyeste splittelsen skjedde Oct 21, 2026.
Én VKTX-aksje kjøpt før Oct 21, 2026 tilsvarer i dag 0 VKTX-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|